Cuba Medical News. Hepatitis Treatment in Cuba. Novel Vaccines and Medications
Cuba Registers Vaccine against Chronic Hepatitis B
Cuba's HeberNasvac® vaccine, unique in the world for treating patients infected by the virus of chronic Hepatitis B, obtained the health registration by the Center for State Control of Drugs, Equipment Medical Devices. This was announced at the 2nd International Congress on Research, Development and Technological Innovation in the Pharmaceutical Industry.
Developed by the Center for Genetic Engineering and Biotechnology (CIGB), the therapeutic vaccine is supported by patents granted in the most demanding markets, and has more than 20 scientific publications by Cuban researchers with foreign contributors. Among them, from the Ehime University in Japan, the Liver Foundation and the Society for the Study of Liver of Bangladesh, the Pasteur Institute of France, the Venezuelan Institute for Scientific Research, and the University of Hanover, of Germany.
Cuban scientists discover neuro-protective qualities of new molecule JM-20 for treatment of brain ischemia
Cuban researchers have discovered pharmacological evidence of neuro-protective qualities of new molecule called JM-20, opening up promising prospects for the treatment of cerebral ischemia.
The discovery means that next phase of clinical trails on humans can take place. If successful and the neuro-protective qualities of JM-20 are proven, this could lead to the creation of a medication with effective therapeutic properties to treat brain ischemia and its associated effects. The molecule and its derivatives are protected under a 100% national patent.
Cuba performs over 5,100 successful kidney transplants in 4 decades
Cuba has successfully performed over 5,100 kidney transplants since 1970, an achievement on par with that of the developed nations. In a 42-year period Cuban surgeons have undertaken 4,751 kidneys transplants with deceased donors and 397 with living donors, all free of charge for Cubans.
The living donors are close relatives, such as parents, brothers and sons, of the patients, the only donors Cuban clinics accept for that kind of transplants.
There are 43 hospitals distributed around the country with a multidisciplinary group that attends cadaveric donors with encephalic death. The donor rate in Cuba oscillates between 15 and 18 per million; 90% of them are from cadaveric donors. This program includes 47 dialysis centers throughout the country with 2300 patients as supported by a National Coordinating Center at The Nephrology Institute.
Nine health centers in the country can perform transplants with living donors, five of them in Havana.
Almost 400 liver transplants in Cuba
Cuba has carried out nearly 400 liver transplants since it began this complex proceeding on January 26, 1986, to date. And the results are similar to those of first world nations, despite various limitations on Cuba due to the blockade of United States for over 50 years.
Currently, these grafts are done at two Havana hospitals and William Soler Pediatric Hospital, the latter with a living donor program.
Liver transplantation is a common therapeutics disseminated worldwide to treat patients with acute or chronic liver irreversible illnesses, for which there are no curative treatments. Such transplantation is extremely complex due to the peculiarities of the patient and the surgery that includes within a multidisciplinary group high level anesthetists and surgeons who make dissections and vascular anastomosis necessary to remove the diseased organ and graft the healthy one. According to statistics, in the first world countries the cost of a liver transplant in the first year ranges from 75,000 to 150,000 dollars, and for Cubans is offered for free.
New Cuban vaccine for treatment of chronic hepatitis B is currently undergoing clinical trials in Cuba and eight Asian countries, with cooperation of French company Abivax.
The new Cuban medicine called HeberNasvac was developed by researchers of the Center for Genetic Engineering and Biotechnology (CIGB). The new drug that is administered nasally and subcutaneously and has proved to be more effective and safer than all other existing medications available for this virus in the world today.
Studies of clinical evaluation have been approved by regulatory authorities in Australia, New Zealand, South Korea, Singapore, Taiwan, Hong Kong, the Philippines and Thailand.
The protocol for the medical evaluation was designed by leading experts contracted by Abivax along with Cuban scientists, according to officials at the CIGB, who confirmed the satisfactory progress of the trials in Asia, one of the regions most affected by the virus.
A second clinical study of the new vaccine, still in the phase of recruiting the sample of patients, will take place at 13 medical centers in Cuba and will benefit 160 patients on the island.
In Cuba use of the vaccine is expected to begin in 2016, after obtaining the approval of the sanitary registration granted by the Center for State Control of Medicaments, Equipment and Medical Devices (CECMED).
In November 2014, Cuba announced that preventive vaccines against cholera, pneumococcus and hepatitis B were being prepared for registration and application this year. All were described as highly innovative, safe and effective products by medical authorities on the island.
According to the World Health Organization, chronic liver disease caused by the hepatitis B virus is one of the main causes of liver cancer, liver cirrhosis, and other complications such as esophageal varicose veins. Each year there are on the planet about one million deaths related to infection by this virus.
Leading experts from the United States to attend 27th International Congress of Orthopedics and Traumatology in Varadero
Leading experts from the United States, previously limited from participating due to the laws of the criminal economic, commercial and financial blockade endured by the Cuban people for over 50 years, will offer a symposium on the treatment of shoulder pathologies, where Cuba will present the development of the RALCA external fixator, introduced in surgical procedures on the island. Other key topics of the event include back operations, foot deformities, shoulder, hip and ankle arthroscopy, minimally invasive surgery, infections, complex hip conditions in older adults, injuries in high performance sports (Sports Traumatology) and other developments in the field of orthopedics.More on latest developments in orthopedics and traumatology in Cuba and costs...
Malaysian Firm to Commercialize Cuban Vaccine against Cancer in London
Cuba, Jul 30, 2015. Malaysia's biotechnology firm Bioven, which conducts clinical Phase III trials of a promising Cuban vaccine against cancer, plans to list in London after a fruitful cooperation with Cuba. The relationship of Cuba with Bioven, of which the Malaysian government is one of its major shareholders, is an example of South-South cooperation. Since 2008, through an agreement with the Center of Molecular Immunology (CIM) that created the vaccine, Bioven carries out the clinical development of the Cuban vaccine in Europe and part of Asia and Oceania. Since then, Bioven placed the drug, which targets non-small lung cancer cells, in a larger posterior test, and its presence in the Alternative Investment Market, the junior stock market of London, can help speed up commercial thrust. The medication is a kind of immunotherapy that targets proteins called EGF (epidermal growth factor), over expressed by cancer cells. The Phase III trial, the last one before regulatory approval, started in May with the participation of 419 patients from ten countries. Much of the clinical development work is done in Scotland, in cooperation with the Beatson Cancer Institute in Glasgow.
Proctokinasa, safe and effective suppository for the treatment of acute hemorrhoids
Cuban researchers of the Center for genetic engineering and biotechnology (CIGB), in collaboration with Juan Bruno Zayas Hospital, of Santiago de Cuba, created an effective and safe drug as a suppository for the treatment of acute hemorrhoids, based on the use of recombinant streptokinase that showed its efficacy and safety vs. hydrocortisone acetate-based suppositories in acute hemorrhoidal disease.
After more than five years of clinical trials in health institutions of twelve provinces, involving 820 patients, the drug obtained its registration in August 2012 with the name of Proctokinasa and is destined to become the most recommended therapy against acute hemorrhoids in Cuba, depending on growth of productive capacities in nearest future.
Unlike existing local application formulas that focus their main action in reducing inflammation and pain, these suppositories, in addition to meeting the above functions, manage removal of thrombi or clots of blood in the affected anal region, resulting in an improvement of the clinical diagnosis of the hemorrhoid crisis in the range of 75 to 90% of the people treated on the fifth day of employment.
Hemorrhoids are varicose veins or inflammation of the veins of anus. Its key symptom is pain, and they tend to be caused by chronic constipation, diarrheal diagnosis, pregnancy or aging.
Randomized, controlled clinical trials of medical treatments for acute hemorrhoidal disease with recombinant streptokinase suppositories, based on thrombolysis, show a significant efficacy advantage with respect to hydrocortisone acetate, a widely-used, over-the-counter product.
Correo Cientifico Medico de Holguin 2006;10(4)
Hospital Provincial Docente Clinico quirurgico "Lucia Iniguez Landin" Holguin.
Vitiligo en edad pediatrica, Centro de Histoterapia Placentaria Holguin. Cuba. 1999-2004.
Vitiligo at Pediatric Age. Placental Histotherapy Center. Holguin. Cuba. 1999-2004.
Ines Delfina Castilla Huapaya1, Elio Lozano Alvarez2, Onelia M. Hernandez Marrero3, Miriam Bauza Leyva4, Noemi Batista Munoz5.
1 Especialista de primer grado en Dermatologia.
2 Especialista de segundo grado en Endocrinologia. Vicedirector docente del Hospital Lucia Iniguez.
3 Especialista de primer grado en Dermatologia. Profesor Instructor. Jefa de Catedra. Jefa provincial en Dermatologia
4 Especialista de primer grado en Dermatologia. Profesor Asistente. Jefa de Centro Provincial de Histoterapia Placentaria de Holguin.
5 Especialista de primer grado en Dermatologia. Profesor Instructor.
Se realizo una investigacion de serie de casos en el Centro de Histoterapia Placentaria de Holguin, en el periodo comprendido entre 1999 y 2004 en 186 ninos con el diagnostico clinico e histopatologico de vitiligo, con el objetivo de determinar algunos aspectos clinicos y epidemiologicos de la enfermedad y su respuesta terapeutica a la Melagenina. Predomino el grupo de edad de 10-14 anos con 76 enfermos (40,86%), el sexo femenino con 46 (43,40%) y el tiempo de evolucion fue de 4?6 meses en 70 pacientes (37,63%). Entre los posibles factores desencadenantes ocupo el primer lugar la intranquilidad, presente en 53 enfermos (28,49%). Hubo respuesta favorable al tratamiento con remision parcial de las lesiones en 133 casos (71,51%). Se encontro asociacion con las atopias en 37 pacientes (19,89%). Se concluyo que el vitiligo es una enfermedad frecuente en la edad pediatrica por lo que se les debe dar seguimiento a estos enfermos.
An investigation of a serie of cases in the Holguin Center of Placental Histotherapy, in the period between 1999-2004, on 186 children with a diagnosis of histopathologic vitiligo was carried out with the objective of determining some clinical and epidemic aspects of the illness and their therapeutic answer to Melagenina with a predominance of the group 10-14 years with 76 sick persons(40.86%). And 46 females with 43.40%. The time of evolution was from 4 to 6 months in 70 patients(37.63%). Among the possible precipitating factors, uneasiness occupico the first place, with 53 sick persons (28.49%). There was, am favorable response to the treatment with partial remission of the lesion in133 cases (71.50%). Lesions in the trunk occupied the first- place, 59 patients(31.72%). Lesions associated with atrophies were found in 37 patients (19.89%. It was stated that vitiligo is a frequent disease at pediatric age, so there should be a follow-up these patients.
El viiligo es una enfermedad que interesa la piel, de etiologia desconocida, que afecta aproximadamente entre el 1-2 % de la poblacion mundial, independientemente de la edad, sexo y raza. Aproximadamente el 25% son ninos.1 Es una enfermedad relativamente comun, del 2 al 8% de los pacientes dermatologicos la presenta y es mas notorio en las personas de piel oscura. 2